Effects of nanocurcumin supplementation on metabolic syndrome: A systematic review and meta-analysis of randomized controlled trials
Pharmacological Research · 2025-03 · 213 · 107641
DOI: 10.1016/j.phrs.2025.107641 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Pharmacological Research, 2025-03. Verfasst von Gofarana Wilar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang 45363, Indonesia. Electronic address: g.wila…. Hauptthemen laut MEDLINE: Metabolic Syndrome, Curcumin, Dietary Supplements. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitas Padjadjaran.
Abstract (Originalsprache)
BACKGROUND: Metabolic syndrome (MetS) encompasses metabolic risk factors like elevated blood glucose, abnormal lipid levels, and hypertension. Nanocurcumin, a nanoscale formulation of curcumin, may offer therapeutic benefits for MetS management. This systematic review and meta-analysis evaluates the impact of nanocurcumin supplementation on key MetS parameters. METHODS: A systematic literature search identified 20 randomized controlled trials (RCTs) with 1394 participants. Data were pooled using a random-effects model, and standardized mean differences (SMDs) were calculated for key outcomes. RESULTS: Nanocurcumin supplementation significantly improved waist circumference (WC) (standardized mean difference (SMD): -0.30 cm), fasting blood sugar (FBS) (SMD: -0.34 mg/dL), HbA1c (SMD: -0.33 %), and quantitative insulin sensitivity check index (QUICKI) score (SMD: 0.73). Lipid profile parameters, including total cholesterol (SMD: -0.18 mg/dL), LDL-C (SMD: -0.16 mg/dL), and HDL-C (SMD: 0.32 mg/dL), also reduced significantly. Improvement in diastolic blood pressure (DBP) (SMD: -0.32 mmHg), total antioxidant capacity (TAC) (SMD: 0.44 mmol/L), malondialdehyde (MDA) (SMD: -0.37 mmol/L), tumor necrosis factor-α (TNF-α) (SMD: -2.30 ng/L), interleukin-6 (IL-6) (SMD: -1.07 ng/L), and high-sensitivity C-reactive protein (hs-CRP) (SMD: -0.34 mg/L) were observed. CONCLUSION: Nanocurcumin supplementation significantly improves multiple MetS-related parameters, including anthropometric measures, glycemic control, lipid profile, blood pressure, oxidative stress markers, and inflammatory biomarkers. These findings highlight nanocurcumin's potential as an effective adjunctive therapy for managing MetS. However, the variability in study participant ages, treatment durations, and sample sizes suggests the need for further well-designed RCTs to establish optimal usage guidelines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang 45363, Indonesia. Electronic address: g.wilar@unpad.ac.id.
- Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang 45363, Indonesia; Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padj…
- Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan; Department of CNS Drug Innovation, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai…
- Department of Biophysical Chemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan.
- Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan.
- Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang 45363, Indonesia.
Förderung
- Universitas Padjadjaran
Zitieren
APA
Wilar, G., Suhandi, C., Fukunaga, K., Shigeno, M., Kawahata, I., Abdulah, R., & Sasaki, T. (2025). Effects of nanocurcumin supplementation on metabolic syndrome: A systematic review and meta-analysis of randomized controlled trials. Pharmacological Research, 213, 107641. https://doi.org/10.1016/j.phrs.2025.107641
Vancouver
Wilar G, Suhandi C, Fukunaga K, Shigeno M, Kawahata I, Abdulah R, et al. Effects of nanocurcumin supplementation on metabolic syndrome: A systematic review and meta-analysis of randomized controlled trials. Pharmacological Research. 2025;213:107641. doi:10.1016/j.phrs.2025.107641
BibTeX
@article{Wilar2025,
author = {Wilar, Gofarana and Suhandi, Cecep and Fukunaga, Kohji and Shigeno, Masanori and Kawahata, Ichiro and Abdulah, Rizky and Sasaki, Takuya},
title = {Effects of nanocurcumin supplementation on metabolic syndrome: A systematic review and meta-analysis of randomized controlled trials},
journal = {Pharmacological Research},
year = {2025},
volume = {213},
pages = {107641},
doi = {10.1016/j.phrs.2025.107641}
}
EUVIMED